Aberrant expression of the DUX4 gene in the affected muscles is widely regarded as a key driver of FSHD pathogenesis, making gene therapy approaches, such as the use of AOs targeting DUX4, a promising therapeutic strategy. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.